文献速递认知障碍与痴呆

LipiDiDiet 试验:特定复合营养素干预前驱期阿尔茨海默病 24 个月结果

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
PubMed 文献 · Lancet Neurol · 2017-10-30

LipiDiDiet 是一项 24 个月随机双盲对照多中心试验,纳入 311 例前驱期阿尔茨海默病患者,比较每日 Fortasyn Connect 饮品与对照饮品。次要终点认知、功能及海马萎缩的组间差异有观察。

要点

  • 主要终点 NTB 评分 24 个月组间差异无统计学意义。
  • 对照组认知下降远低于预期,主要终点把握度不足。
  • 次要终点认知、功能及海马萎缩见组间差异,需进一步研究。

核心结论

  • 在 24 个月内,Fortasyn Connect 对前驱期阿尔茨海默病患者的 NTB 主要终点无显著影响。
  • 该人群认知下降远低于预期,导致主要终点把握度不足。
  • 测量认知与功能的疾病进展次要终点及海马萎缩观察到组间差异。

研究设计与样本

  • LipiDiDiet 为 24 个月随机、对照、双盲、平行组、多中心试验,含可选 12 个月双盲延长期。
  • 试验在芬兰、德国、荷兰和瑞典的 11 个中心开展。
  • 纳入按国际工作组(IWG)-1 标准定义的前驱期阿尔茨海默病患者。
  • 311 例参与者按 1:1 随机分配至活性产品组(n=153)或对照组(n=158)。
  • 活性产品为每日一次 125 mL 含 Fortasyn Connect 的饮品,主要终点为神经心理测验组合(NTB)评分变化。

主要发现

  • 66 例(21%)参与者退出研究。

关键数值与推荐

  • 前驱期阿尔茨海默病按 IWG-1 标准定义。
  • 主要终点为 NTB 评分变化,采用改良意向治疗分析。
  • 安全性分析纳入所有至少服用一剂研究产品的参与者。

临床怎么用

  • 当前证据不支持 Fortasyn Connect 用于改善前驱期阿尔茨海默病主要认知终点。
  • 需更大样本、更长疗程或更敏感主要终点的营养干预研究进一步验证。

局限性

  • 该人群认知下降远低于预期,主要终点把握度不足。
  • 66 例(21%)参与者退出研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease dementia. LipiDiDiet investigated the effects of Fortasyn Connect on cognition and related measures in prodromal Alzheimer's disease. Here, we report the 24-month results of the trial. METHODS: LipiDiDiet was a 24-month randomised, controlled, double-blind, parallel-group, multicentre trial (11 sites in Finland, Germany, the Netherlands, and Sweden), with optional 12-month double-blind extensions. The trial enrolled individuals with prodromal Alzheimer's disease, defined according to the International Working Group (IWG)-1 criteria. Participants were randomly assigned (1:1) to active product (125 mL once-a-day drink containing Fortasyn Connect) or control product. Randomisation was computer-generated centrally in blocks of four, stratified by site. All study personnel and participants were masked to treatment assignment. The primary endpoint was change in a neuropsychological test battery (NTB) score. Analysis was by modified intention to treat. Safety analyses included all participants who consumed at least one study product dose. This trial is registered with the Dutch Trial Register, number NTR1705. FINDINGS: Between April 20, 2009, and July 3, 2013, 311 of 382 participants screened were randomly assigned to the active group (n=153) or control group (n=158). Mean change in NTB primary endpoint was -0·028 (SD 0·453) in the active group and -0·108 (0·528) in the control group; estimated mean treatment difference was 0·098 (95% CI -0·041 to 0·237; p=0·166). The decline in the control group was less than the prestudy estimate of -0·4 during 24 months. 66 (21%) participants dropped out of the study. Serious adverse events occurred in 34 (22%) participants in the active group and 30 (19%) in control group (p=0·487), none of which were regarded as related to the study intervention. INTERPRETATION: The intervention had no significant effect on the NTB primary endpoint over 2 years in prodromal Alzheimer's disease. However, cognitive decline in this population was much lower than expected, rendering the primary endpoint inadequately powered. Group differences on secondary endpoints of disease progression measuring cognition and function and hippocampal atrophy were observed. Further study of nutritional approaches with larger sample sizes, longer duration, or a primary endpoint more sensitive in this pre-dementia population, is needed. FUNDING: European Commission 7th Framework Programme.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017. PMID: 29097166. doi:10.1016/S1474-4422(17)30332-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。